Last reviewed · How we verify
NCT06642844: PHARBEVACOL
Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
Phase 3 trial testing Avastin, 25 Mg/mL Intravenous Solution in Unresectable Metastatic Colorectal Cancer in 244 participants. Not yet recruiting.
30 October 2028
Quick facts
| Lead sponsor | University Hospital, Tours |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 244 |
| Start date | 30 October 2024 |
| Primary completion | 30 October 2028 |
| Estimated completion | 30 October 2029 |
Drugs / interventions tested
- Avastin, 25 Mg/mL Intravenous Solution — full drug profile →
Conditions studied
- Unresectable Metastatic Colorectal Cancer — all drugs for Unresectable Metastatic Colorectal Cancer →
Sponsor
University Hospital, Tours
Who can join
Adults 18 to 99, any sex, with Unresectable Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bevacizumab is a standard drug for metastatic colorectal cancer (mCRC) in combination with cytotoxic chemotherapy. However, inter-individual pharmacokinetic variability was observed for bevacizumab and an exposure-response relationship for efficacy was described for bevacizumab in mCRC patients treated with 1st-line bevacizumab-based chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06642844
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Unresectable Metastatic Colorectal Cancer
Currently open trials in the same condition.
- NCT04991948 — Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer · Phase 1 · recruiting
- NCT03692429 — alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Recep · Phase 1 · recruiting
Other University Hospital, Tours trials
Trials by the same sponsor.
- NCT07452978 — Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence · Phase 2 · not yet recruiting
- NCT07443800 — Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia · NA · not yet recruiting
- NCT07251530 — Communication Enhancement Among Ventilated Patients in Intensive Care · not yet recruiting
- NCT07189338 — Apneic Oxygenation With High-flow Nasal Oxygenation After Preoxygenation With Noninvasive Ventilation Before Intubation · NA · not yet recruiting
- NCT07054112 — Efficacy of Live Online Course Mindfulness Program on Perceived Fatigue in Hemodialysis Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06642844 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Tours
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06642844.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing